Anti-phospholipid antibodies are associated with response to interferon-betaia treatment in MS: Results from a 3-year longitudinal study

Neurological Research

Volumn 34, Issue 8, 2012, Pages 761-769

  Zivadinov, Robert ^a,b   Ramanathan, Murali ^a   Ambrus, Julian ^a   Hussein, Sara ^a   Ramasamy, Deepa P ^a   Dwyer, Michael G ^a   Bergsland, Niels ^a   Minagar, Alireza ^c   Weinstock Guttman, Bianca ^b  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b JACOBS NEUROLOGICAL INSTITUTE   (United States)

^c Louisiana State University Health Sciences Center at Shreveport   (United States)

Author keywords

Anti phospholipid antibodies; Atrophy; Diffusion weighted imaging; Disability; IFN beta1a; Lesions; Longitudinal; Magnetization transfer imaging; Multiple sclerosis; Positivity; Prospective; References; Relapses; Responsiveness

Indexed keywords

BETA1A INTERFERON; PHOSPHOLIPID ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BRAIN SIZE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DISABILITY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; ENTROPY; FEMALE; FOLLOW UP; GENERAL CONDITION DETERIORATION; HUMAN; LONGITUDINAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; TISSUE INJURY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; ATROPHY; BRAIN; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROIMAGING; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84866234750     PISSN: 01616412     EISSN: 17431328     Source Type: Journal    
DOI: 10.1179/1743132812Y.0000000076     Document Type: Article

References (45)

1. Frohman EM, Racke MK, Raine CS. Multiple sclerosis - the plaque and its pathogenesis. N Engl J Med. 2006;354(9):942-955.
2. Garg N, Weinstock-Guttman B, Bhasi K, Locke J, Ramanathan M. An association between autoreactive anti- bodies and anti-interferon-beta antibodies in multiple sclerosis. Mult Scler. 2007;13(7):895-899.
3. Szmyrka-Kaczmarek M, Pokryszko-Dragan A, Pawlik B, Gruszka E, Korman L, Podemski R, et al. Antinuclear and antiphospholipid antibodies in patients with multiple sclerosis. Lupus. 2012;21(4):412-420.
4. Tourbah A, Clapin A, Gout O, Fontaine B, Liblau R, Bat-teux F, et al. Systemic autoimmune features and multiple sclerosis: a 5-year follow-up study. Arch Neurol. 1998;55(4):517-521.
5. Karussis D, Leker RR, Ashkenazi A, Abramsky O. A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity? Ann Neurol. 1998;44(4):629-634.
6. Collard RC, Koehler RP, Mattson DH. Frequency and significance of antinuclear antibodies in multiple sclerosis. Neurology. 1997;49(3):857-861.
7. Horstman LL, Jy W, Bidot CJ, Ahn YS, Kelley RE, Zivadinov R, et al. Antiphospholipid antibodies: paradigm in transition. J Neuroinflammation. 2009;6:3.
8. Rodrigues CE, Carvalho JF, Shoenfeld Y. Neurological manifestations of antiphospholipid syndrome. Eur J Clin Invest. 2010;40(4):350-359.
9. Arnson Y, Shoenfeld Y, Alon E, Amital H. The antipho- spholipid syndrome as a neurological disease. Semin Arthritis Rheum. 2010;40(2):97-108.
10. Hughes G. Hughes syndrome: the antiphospholipid syndrome - a clinical overview. Clin Rev Allergy Immunol. 2007;32(1):3-12.
11. Brey RL, Muscal E, Chapman J. Antiphospholipid antibodies and the brain: a consensus report. Lupus. 2011;20(2):153-157.
12. Bidot CJ, Horstman LL, Jy W, Ahn ER, Jimenez JJ, Yaniz M, et al. Clinical and neuroimaging correlates of antiphospholipid antibodies in multiple sclerosis: a preliminary study. BMC Neurol. 2007;7(1):36.
13. Stosic M, Ambrus J, Garg N, Weinstock-Guttman B, Ramanathan M, Kalman B, et al. MRI characteristics of patients with antiphospholipid syndrome and multiple sclerosis. J Neurol. 2010;257(1):63-71.
14. Roussel V, Yi F, Jauberteau MO, Couderq C, Lacombe C, Michelet V, et al. Prevalence and clinical significance of anti- phospholipid antibodies in multiple sclerosis: a study of 89 patients. J Autoimmun. 2000;14(3):259-265.
15. Garg N, Zivadinov R, Ramanathan M, Vasiliu I, Locke J, Watts K, et al. Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients. J Neuroimmunol. 2007;187(1-2):159-165.
16. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera. R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306.
17. Abo SM, DeBari VA. Laboratory evaluation of the antipho- spholipid syndrome. Ann Clin Lab Sci. 2007;37(1):3-14.
18. Carrillo-Mora P, Gonzalez-Villalva A. Clinical characteristics and presence of antiphospholipid antibodies (anticardiolipin- beta2GP-1) cerebrospinal fluid and serum of in a series of patients with multiple sclerosis in Mexico. Neurologia. 2010;25(2):71-77.
19. Ijdo JW, Conti-Kelly AM, Greco P, Abedi M, Amos M, Provenzale JM, et al. Anti-phospholipid antibodies in patients with multiple sclerosis and MS-like illnesses: MS or APS? Lupus. 1999;8(2):109-115.
20. Sastre-Garriga J, Reverter JC, Font J, Tintore M, Espinosa G, Montalban X. Anticardiolipin antibodies are not a useful screening tool in a nonselected large group of patients with multiple sclerosis. Ann Neurol. 2001;49(3):408-411.
21. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Ann Neurol. 2005;58(6):840-846.
22. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46(4):907-911.
23. Zivadinov R, Heininen-Brown M, Schirda CV, Poloni GU, Bergsland N, Magnano CR, et al. Abnormal subcortical deep- gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study. Neuroimage. 2012;59(1):331-339.
24. Smith SM, Zhang Y, Jenkinson M, Chen J, Matthews PM, Federico A, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage. 2002;17(1):479-489.
25. Tavazzi E, Dwyer MG, Weinstock-Guttman B, Lema J, Bastianello S, Bergamaschi R, et al. Quantitative diffusion weighted imaging measures in patients with multiple sclerosis. Neuroimage. 2007;36(3):746-754.
26. Zivadinov R, Weinstock-Guttman B, Benedict R, Tamatio- Blanco M, Hussein S, Abdelrahman N, et al. Preservation of gray matter volume in multiple sclerosis patients with the Met allele of the rs6265 (Val66Met) SNP of brain derived neurotrophic factor (BDNF). Hum Mol Genet. 2007; 16(22):2659-2668.
27. Pierangeli SS, Chen PP, Gonzalez EB. Antiphospholipid antibodies and the antiphospholipid syndrome: an update on treatment and pathogenic mechanisms. Curr Opin Hematol. 2006;13(5):366-375.
28. Kalman B, Laitinen K, Komoly S. The involvement of mitochondria in the pathogenesis of multiple sclerosis. J Neuroimmunol. 2007;188(1-2):1-12.
29. Grunewald T, Burmester GR, Schuler-Maue W, Hiepe F, Buttgereit F. Anti-phospholipid antibodies and CD5+ B cells in HIV infection. Clin Exp Immunol. 1999;115(3):464-471.
30. Popescu BF and Lucchinetti CF. Meningeal and cortical grey matter pathology in multiple sclerosis. BMC Neurol. 2012;12(1):11.
31. Miesbach W, Gilzinger A, Gokpinar B, Claus D, Scharrer I. Prevalence of antiphospholipid antibodies in patients with neurological symptoms. Clin Neurol Neurosurg. 2006;108(2): 135-142.
32. Sanna G, Bertolaccini ML, Hughes GR. Hughes syndrome, the antiphospholipid syndrome: a new chapter in neurology. Ann NY Acad Sci. 2005;1051:465-486.
33. Zivadinov R, Bergsland N, Stosic M, Sharma J, Nussenbaum F, Durfee J, et al. Use of perfusion- and diffusion-weighted imaging in differential diagnosis of acute and chronic ischemic stroke and multiple sclerosis. Neurol Res. 2008;30(8):816-826.
34. Heinzlef O, Weill B, Johanet C, Sazdovitch V, Caillat-Zucman S, Tournier-Lasserve E, et al. Anticardiolipin antibodies in patients with multiple sclerosis do not represent a subgroup of patients according to clinical, familial, and biological char- acteristics. J Neurol Neurosurg Psychiatry. 2002;72(5):647-649.
35. Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007;130(Pt 4):1089-1104.
36. Noronha A. Neutralizing antibodies to interferon. Neurology. 2007;68(24 Suppl 4):S16-S22.
37. Bertolotto A. Neutralizing antibodies to interferon beta: implications for the management of multiple sclerosis. Curr Opin Neurol. 2004;17(3):241-246.
38. Axtell RC, Raman C, Steinman L. Type I interferons: beneficial in Th1 and detrimental in Th17 autoimmunity. Clin Rev Allergy Immunol. 2012; Jan 10 [Epub ahead of print] PMID: 22231516.
39. Weiner HL. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol. 2009;65(3):239-248.
40. Feng X, Reder NP, Yanamandala M, Hill A, Franek BS, Niewold TB, et al. Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis. J Neurol Sci. 2012;313(1-2):48-53.
41. Ciccarelli O, Bagnato F, Mainero C, Salvetti M, Paolillo A, Gasperini C, et al. Antinuclear antibodies and response to IFNbeta-1a therapy in relapsing-remitting multiple sclerosis. Mult Scler. 2000;6(3):137-139.
42. Colosimo C, Pozzilli C, Frontoni M, Farina D, Koudriavtseva T, Gasperini C, et al. No increase of serum autoantibodies during therapy with recombinant human interferon-beta1a in relapsing-remitting multiple sclerosis. Acta Neurol Scand. 1997;96(6):372-374.
43. Zivadinov R, Bakshi R. Role of MRI in multiple sclerosis II: brain and spinal cord atrophy. Front Biosci. 2004;9:647-664.
44. Zivadinov R, Locatelli L, Cookfair D, Srinivasaraghavan B, Bertolotto A, Ukmar M, et al. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy. Mult Scler. 2007;13(4):490-501.
45. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology. 1999;53(8):1698-1704.